VITALIZE: A phase IIb, open-label, multicenter, randomized parallel-group, two-stage, study of maveropepimut-S, pembrolizumab, with or without intermittent low-dose cyclophosphamide, in r/r DLBCL Meeting Abstract
| Authors: | Matasar, M.; Teti, J.; Mody, K.; Fiset, S.; Graff, J. |
| Abstract Title: | VITALIZE: A phase IIb, open-label, multicenter, randomized parallel-group, two-stage, study of maveropepimut-S, pembrolizumab, with or without intermittent low-dose cyclophosphamide, in r/r DLBCL |
| Meeting Title: | ESMO Congress 2022 |
| Journal Title: | Annals of Oncology |
| Volume: | 33 |
| Issue: | Suppl. 7 |
| Meeting Dates: | 2022 Sep 9-13 |
| Meeting Location: | Paris, France |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2022-09-01 |
| Start Page: | S836 |
| End Page: | S837 |
| Language: | English |
| ACCESSION: | WOS:000866211600637 |
| DOI: | 10.1016/j.annonc.2022.07.771 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 646TiP -- Source: Wos |
